These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 11431595)
1. Thiazolidinediones and liver toxicity. Scheen AJ Diabetes Metab; 2001 Jun; 27(3):305-13. PubMed ID: 11431595 [TBL] [Abstract][Full Text] [Related]
2. Hepatotoxicity with thiazolidinediones: is it a class effect? Scheen AJ Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645 [TBL] [Abstract][Full Text] [Related]
5. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Kohlroser J; Mathai J; Reichheld J; Banner BF; Bonkovsky HL Am J Gastroenterol; 2000 Jan; 95(1):272-6. PubMed ID: 10638596 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Lebovitz HE; Kreider M; Freed MI Diabetes Care; 2002 May; 25(5):815-21. PubMed ID: 11978674 [TBL] [Abstract][Full Text] [Related]
7. The thiazolidinediones or "glitazones" a treatment option for type 2 diabetes mellitus. Brown MN Med Health R I; 2000 Apr; 83(4):118-20. PubMed ID: 10821014 [TBL] [Abstract][Full Text] [Related]
8. Case of the month. Hepatic and renal failure in a patient taking troglitazone and metformin. Chaudhry MU; Simmons DL J Ark Med Soc; 2001 Jul; 98(1):16-9. PubMed ID: 11452755 [TBL] [Abstract][Full Text] [Related]
9. Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors. Gegick CG; Altheimer MD Curr Med Res Opin; 2004 Jun; 20(6):919-30. PubMed ID: 15200751 [TBL] [Abstract][Full Text] [Related]
10. Thiazolidinedione hepatotoxicity: a class effect? Tolman KG Int J Clin Pract Suppl; 2000 Oct; (113):29-34. PubMed ID: 11965828 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice. Yamanaka M; Itakura Y; Tsuchida A; Nakagawa T; Noguchi H; Taiji M Diabetes Obes Metab; 2007 Nov; 9(6):879-88. PubMed ID: 17924870 [TBL] [Abstract][Full Text] [Related]
12. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. Strowig SM; Raskin P Diabetes Obes Metab; 2005 Nov; 7(6):633-41. PubMed ID: 16219007 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S; Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and clinical efficacy of pioglitazone. Hanefeld M Int J Clin Pract Suppl; 2001 Sep; (121):19-25. PubMed ID: 11594240 [TBL] [Abstract][Full Text] [Related]
16. Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program. Cluxton RJ; Li Z; Heaton PC; Weiss SR; Zuckerman IH; Moomaw CJ; Hsu VD; Rodriguez EM Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):1-9. PubMed ID: 15546159 [TBL] [Abstract][Full Text] [Related]
17. Thiazolidinediones in type 2 diabetes: a cardiology perspective. Khanderia U; Pop-Busui R; Eagle KA Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014 [TBL] [Abstract][Full Text] [Related]
18. Hepatotoxicity of the thiazolidinediones. Tolman KG; Chandramouli J Clin Liver Dis; 2003 May; 7(2):369-79, vi. PubMed ID: 12879989 [TBL] [Abstract][Full Text] [Related]
19. Pioglitazone and rosiglitazone for diabetes. Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802 [TBL] [Abstract][Full Text] [Related]
20. Sitagliptin: a novel drug for the treatment of type 2 diabetes. Choy M; Lam S Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]